Session Details
[S35]The Path for Bacteriophage as the Pharmaceutical Products in Japan
Fri. Mar 28, 2025 4:45 PM - 6:15 PM JST
Fri. Mar 28, 2025 7:45 AM - 9:15 AM UTC
Fri. Mar 28, 2025 7:45 AM - 9:15 AM UTC
Room 4 (Fukuoka International Congress CenterR: 201 [2F])
Organizer: Tomoko Hanawa (Sch. Med., Kyorin Univ.), Satoshi Tsuneda (Sch. Adv. Sci. Eng., Waseda Univ.)
Bacteriophages that infect bacteria have long been used to treat bacterial infectious diseases. Efforts to apply bacteriophages to the clinical treatment of multidrug-resistant bacteria have been promoted, and their therapeutic effects have been enhanced worldwide. One of the challenges is the development of recombinant phages especially the overcome the weak point of phage. Furthermore, novel phage applications utilizing the property of limited host range of phage, in other words, highly host-specificity of phage, are attracting attention.
In July 2024, the European Pharmacopoeia published standards for the manufacture and administration of phage as a pharmaceutical product. This is expected to make phage therapy more and more practical in the future. Thus, there is a growing possibility that phage will soon be available as a pharmaceutical product in Japan.
In this symposium, various applications of phage as pharmaceuticals will be introduced, and the current status and issues will be discussed to realize phage therapy in Japan.
In July 2024, the European Pharmacopoeia published standards for the manufacture and administration of phage as a pharmaceutical product. This is expected to make phage therapy more and more practical in the future. Thus, there is a growing possibility that phage will soon be available as a pharmaceutical product in Japan.
In this symposium, various applications of phage as pharmaceuticals will be introduced, and the current status and issues will be discussed to realize phage therapy in Japan.
趣旨説明：花輪 智子（杏林大医）
[S35-1]Current status and challenges of phage therapy for multidrug-resistant bacterial infections diseases
○Tomoko Hanawa1, Takeaki Matsuda1,2 (1. Kyorin Univ Sch. Med., Gen Med., 2. Kyorin Univ Sch. Med., TCC)
[S35-2]Phage therapy: Precision editing of the intestinal microbiota and the fitness trade-off
○Jumpei Fujiki1,2, Yi Duan2, Tomohiro Nakamura1,2,3,4, Cristina Llorente2, Derrick Fouts5, Bernd Schnabl2,6, Hidetomo Iwano1,4 (1. Sch. Vet. Med., Rakuno Gakuen Univ., 2. Dept. Med., UCSD, 3. Res. Cent. Drug Vaccine Dev., Natl. Inst. Infect. Dis, 4. Comp. Res. Org., Waseda Univ., 5. Dept. Human Gen Med., JCVI, 6. Dept. Med, VASDHS)
[S35-3]Potential of phage therapy against highly virulent CA-MRSA strains
○Hidemasa Nakaminami1 (1. Sch. Pharm., Tokyo Univ. Pharm. Life Sci.)
[S35-4]A role of live bio therapeutic products including phage therapy as novel therapeutic options in infectious disease by antimicrobial resistant bacteria.
○Atsushi Shiota1,2,3 (1. Keio Univ School of Med, 2. Keio Univ WPI-Bio2Q, 3. Microbiopharm Japan Co. Ltd.)